WCG Clinical Services Division has opened a new office in Tokyo, Japan. WCG’s expanded presence in the Asia-Pacific region aims to strengthen its ability to support increasingly complex, global clinical trials, particularly in the critical areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases. 

“WCG’s Tokyo office will be home to our Clinical Services Division in Asia, as well as a center of excellence for our growing Patient Engagement Group,” said Donald A. Deieso, Ph.D., chairman and chief executive officer of WCG. “By expanding WCG’s footprint abroad, we are helping to ensure that every trial— especially the most complicated and challenging ones—can benefit from our latest advances in trial optimization, signal detection and patient recruitment.”

In the past decade, Asia has become an increasingly attractive destination for clinical research, with a clinical trials infrastructure designed to foster speed, cost effectiveness and quality.  With a population of more than four billion people, Asia also provides research sponsors with access to a large number of patients for clinical trial recruitment.